Antunes Meireles Pedro, Fragoso Sofia, Duarte Teresa, Santos Sidónia, Bexiga Catarina, Nejo Priscila, Luís Ana, Mira Beatriz, Miguel Isália, Rodrigues Paula, Vaz Fátima
Medical Oncology Department, Instituto Português de Oncologia de Lisboa Francisco Gentil, 1099-023 Lisbon, Portugal.
Molecular Pathobiology Research Unit, Instituto Português de Oncologia de Lisboa Francisco Gentil, 1099-023 Lisbon, Portugal.
Cancers (Basel). 2023 Dec 3;15(23):5699. doi: 10.3390/cancers15235699.
BACKGROUND: Germline pathogenic variants (PV) in and genes, which account for 20% of familial breast cancer (BC) cases, are highly penetrant and are associated with Hereditary Breast/Ovarian Cancer Syndrome. Previous studies, mostly including higher numbers of BC patients, yielded conflicting results regarding BC outcomes. In the Portuguese population, BC is diagnosed more frequently than BC. We aimed to compare clinicopathological characteristics and prognosis between BC patients with and mutations and a control group without germline PV (). Furthermore, we explored the frequency and outcomes of risk-reducing surgeries in -mutated patients. METHODS: Prospective follow-up was proposed for patients with a diagnosed PV. For this study, a matched control group (by age at diagnosis, by decade, and by stage at diagnosis) included BC patients without germline PV. We compared overall survival (OS) and invasive disease-free survival (iDFS) within the three groups, and the use of risk-reducing surgeries among the cohort. RESULTS: For a mean follow-up time of 113.0 months, -wt patients showed longer time to recurrence ( = 0.002) and longer OS ( < 0.001). Among patients with mutations, no statistical differences were found, although patients with BC had longer iDFS and OS. Uptake of risk-reducing surgeries (contralateral prophylactic mastectomy and salpingo-oophorectomy) were negative predictors of invasive disease and death, respectively. CONCLUSIONS: Testing positive for a PV is associated with a higher risk of relapse and death in patients with BC in the Portuguese population. Risk-reducing mastectomy and salpingo-oophorectomy were associated with lower incidence of relapse and longer median iDFS and OS, respectively.
背景:BRCA1和BRCA2基因中的胚系致病变异(PV)占家族性乳腺癌(BC)病例的20%,具有高度外显率,并与遗传性乳腺癌/卵巢癌综合征相关。先前的研究大多纳入了较多数量的乳腺癌患者,但关于乳腺癌的预后结果却相互矛盾。在葡萄牙人群中,BRCA2乳腺癌的诊断频率高于BRCA1乳腺癌。我们旨在比较携带BRCA1和BRCA2突变的乳腺癌患者与无胚系PV(野生型)的对照组之间的临床病理特征和预后。此外,我们还探讨了BRCA1突变患者进行降低风险手术的频率和结果。 方法:对诊断为BRCA1或BRCA2 PV的患者进行前瞻性随访。在本研究中,匹配的对照组(按诊断年龄、按年代和按诊断阶段)包括无胚系PV的乳腺癌患者。我们比较了三组患者的总生存期(OS)和无侵袭性疾病生存期(iDFS),以及BRCA1队列中降低风险手术的使用情况。 结果:平均随访时间为113.0个月,BRCA1野生型患者的复发时间更长(P = 0.002),总生存期更长(P < 0.001)。在携带BRCA2突变的患者中,未发现统计学差异,尽管BRCA2乳腺癌患者的iDFS和OS更长。接受降低风险手术(对侧预防性乳房切除术和输卵管卵巢切除术)分别是侵袭性疾病和死亡的负性预测因素。 结论:在葡萄牙人群中,BRCA1或BRCA2 PV检测呈阳性与乳腺癌患者更高的复发和死亡风险相关。降低风险的乳房切除术和输卵管卵巢切除术分别与较低的复发率以及较长的中位iDFS和OS相关。
Cancers (Basel). 2023-12-3
Am J Obstet Gynecol. 2021-11
Mol Genet Genomic Med. 2019-3
Cancers (Basel). 2024-11-30
N Engl J Med. 2021-2-4
N Engl J Med. 2021-2-4
N Engl J Med. 2021-2-4
Hered Cancer Clin Pract. 2018-1-10